World Analysis News Today

Highlights include two head-to-head randomized clinical trials data presentations of UroLift™ System vs. other modalities to treat benign prostatic hyperplasia -Additional studies examine...

CALQUENCE six-year follow-up data reinforce long-term benefit in chronic lymphocytic leukemia, and data across multiple hematology assets showcase breadth of promising early pipeline New,...

/PRNewswire/ -- Theranica, a neuromodulation therapeutics company, is exhibiting and presenting at the upcoming 52nd Annual Child Neurology Society Meeting...

- Eight Presentations on Yescarta and TecartusAdvance Kite's Cell Therapy Leadership - - New Data Highlight Magrolimab's Potential to Alter the Tumor Microenvironment - Gilead Sciences, Inc. (Nasdaq:

– Eight Presentations on Yescarta® and Tecartus® Advance Kite’s Cell Therapy Leadership – – New Data Highlight Magrolimab’s Potential to Alter the Tumor... | June 1, 2023

21 scientific presentations, including 7 late breakers, showcase the breadth of UCBs portfolio, reinforcing commitment to improving the lives of people living...

Press release content from Business Wire. The AP news staff was not involved in its creation.

S&P Global and IHS Markit Update on Pending Merger Following CMAs Phase 1 Findings NEW YORK & LONDON -- Oct. 19, 2021-- S&P Global and IHS Markit ... | October 22, 2021

LONDON (dpa-AFX) - S&P Global (SPGI) and IHS Markit (INFO) announced Tuesday that the UK Competition and Markets Authority or CMA, has approved their merger, saying it does not raise potential

S&P Global (NYSE: SPGI) and IHS Markit (NYSE: INFO) today provided the following update regarding the decision by the UK Competition and Markets Authority ('CMA') that the merger of S&P Global and IHS